Re: Zenith trial partners
in response to
by
posted on
Jan 31, 2023 06:44AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Resverlogix and Zenith have several directors in common and thus by definition, are considered related parties. Like it or not, Donald J. McCaffrey happens to be the Chairman of the Board for both Corporations. As I understand it, the Chairman can choose to do what he sees fit with or without the approval of the shareholders for the benefit of either corporation.
We mustn't forget that Resverlogix has been supporting Zenith since its inception financially and otherwise. Zenith without the lifelong support from Resverlogix would not have been able to survive on its own all these years.
I see nothing wrong with one company coming to the aid of the other, especially when that support in this instance has been one-sided for a long time. And the fact that most of Zenith's shareholders are also shareholders of Resverlogix.
The perceived conflict of interest, in this case, runs in both directions.
"All for one and one for all" ... Koo :)